mRNA Therapeutics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology), By Type (Prophylactic Vaccines, Therapeutic Drugs), By End-use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global mRNA therapeutics market size was valued at USD 39.90 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 1.7% from 2022 to 2030. RNA-based therapeutics have attracted a lot of attention in recent years owing to their high potential in treating chronic diseases. Furthermore, in terms of production, distribution, and safety, RNA vaccines provide a number of benefits over DNA vaccines. They have also shown promise in human clinical studies, which has increased the demand for mRNA vaccines and therapeutics. In addition, the number of mRNA-based vaccine therapeutics inoncology clinical trialshas dramatically expanded as a result of the success of Moderna's and Pfizer- BioNTech's vaccines against COVID-19. Furthermore, barring the COVID-19 trials in cancer patients, 2021 has seen the second-highest number of mRNA vaccine trials for cancer patients, thus propelling the industry growth.

Due to the rising number of COVID-19 patients around the world and the significant external financing for the manufacturing of mRNA-based COVID-19 vaccines, the COVID-19 pandemic has favorably impacted the growth of the global market. Additionally, when new strains of the SARS-COVID-19 virus appear in numerous nations throughout the world, demand for mRNA vaccines witness a sharp rise due to their potent protection against these strains. As a result, the usage of these mRNA-based products is projected to increase during the COVID-19 pandemic and result in market growth.

此外,信使rna已经成为promising therapeutic tool owing to recent technological advancements such as improved stability, translation, and delivery techniques. Indeed, mRNA vaccines have paved the way for new pharmacological areas and emerged as a prominent therapeutic class. These mRNA vaccines support next-generation vaccinations, ushering in a new era in vaccine development. For instance, in March 2020, Moderna, Inc. and the National Institute of Allergy and Infectious Diseases jointly developed the mRNA-1273 (NIAID). It shows 94.1% efficacy in symptomatic prevention from COVID-19 and in December 2020, received emergency use authorization from the US Food & Drug Administration (US FDA) for widespread immunization of people. Additionally, mRNA therapies, a rapidly growing class of medications for numerous diseases, will alter the accepted standard of service and advance customized medicine. As a result, the demand for mRNA-based products is anticipated to grow in the coming years.

This market growth is fueled by the rising prevalence of chronic diseases like cancer, heart disease, respiratory, CKD, and rare diseases like propionic acidemia, methylmalonic acidemia, glycogen disease, phenylketonuria, and metabolic and immune disorders. For instance, according to Globocan, in December 2020, there were 19.3 million new cases of cancer worldwide and 10 million cancer-related deaths were reported. Furthermore, the popularization of mRNA vaccines; the development of personalized therapeutics for cancer; and a strong pipeline of new products increase the demand for mRNA vaccines and therapeutics, thus propelling the industry growth during the projection period.

Increased investments by operating players for the production of advanced and effective therapeutics and vaccines are likely to support industry growth throughout the projected timeframe. For instance, in April 2021, in a joint venture with Axcelead, Inc., American mRNA therapeutic developer Arcturus Therapeutics formed a Japanese company in Chiba Prefecture and is constructing a production facility in Minamisoma City, Fukushima Prefecture. Such investments are likely to supplement the industry growth in the coming years.

Application Insights

The infectious disease segment led the market and held 100% revenue share in 2021. The increasing adoption of mRNA-based vaccines, a high number of candidates entering clinical trials for various infectious diseases, and the COVID-19 outbreak in late 2019 are anticipated to drive the market over the forecast period. The oncology segment is expected to expand at a lucrative rate over the forecast period. As per the World Health Organization (WHO) estimates, cancer accounted for approximately 10 million deaths in 2020, making it the leading cause of death globally.

此外,肺、结肠、直肠、肝、胃、and breast cancers are some of the prevalent cancers that cause death. As a result, rising chronic illness incidence would ultimately increase the need for mRNA cancer vaccines and therapies, driving the market over the forecast period. Additionally, the lack of precision cancer therapy medications is pressuring the government and a number of important players to invest extensively in R&D. As a result, the demand for cancer vaccines and treatments is rising, thus driving the industry over the forecast period.

Type Insights

The prophylactic vaccines segment dominated the market and captured 100% share in 2021. According to the article in Nature's opinion, prophylactic vaccines are the focus of current R&D efforts, with 77% of mRNA businesses having at least one preventive vaccine in development. Additionally, COVID-19 products account for the vast majority of prophylactic vaccine revenues in the near term, while other vaccines for illnesses including influenza and respiratory syncytial virus also contribute to the segment growth.

Increased mergers and alliances and increased R&D efforts by pharmaceutical companies to improve various preventative vaccination kinds have a further impact on the market growth. For instance, in June 2022, Pfizer and Valneva announced the closing of equity investment for the development and commercialization of prophylactic vaccines for infectious diseases.

End-use Insights

The hospitals and clinics segment captured the largest revenue share of over 60.0% in 2021 and is expected to register the fastest rate during the forecast period. The widespread use of vaccines and therapeutics to treat a variety of chronic diseases is moving the market for personalized pharmaceuticals forward. The segment is also being driven by the increasing number of patients visiting hospitals and clinics.

Additionally, a rise in the number of patients with cancer, influenza, infectious diseases, and respiratory illnesses is expected to fuel the market growth. For instance, according to an NCBI report, in 2019, the WHO estimates that up to 500,000 people worldwide die from influenza each year and approximately one billion people are sick, thus contributing to the expansion of hospitals and healthcare clinics.

Regional Insights

North America dominated the market with over 35.0% share in 2021 and will emerge as the fastest-growing region during the forecast period. The availability of significant research funding, expanding federal programs toward RNA-based medicines, and increasing number of clinical trials will drive the market in North America. For instance, in November 2020, The National Institutes of Health (NIH), the Defense Department, and federally funded academic laboratories have all supported Graham and others' basic research, which has been a crucial component in the quick development of vaccinations against COVID-19. Since the pandemic started, the government has invested an additional $10.5 billion in vaccine manufacturers to quicken the delivery of their products.

Europe captured the second-largest revenue share in 2021 owing to the increased patient population and awareness regarding rare genetic diseases. Moreover, there are major players operating in Europe, and there is an increasing need for mRNA vaccines and therapeutics in the region to create transformational treatments. For instance, as part of the U.S. biotech's expansion to "enable the delivery of mRNA vaccines and therapies locally," Moderna is expanding its wings across Europe (Denmark, Belgium, the Netherlands, Poland, Norway, and Sweden), which will increase the demand for mRNA vaccines and further drive the market over the forecast period.

Key Companies & Market Share Insights

Key players are implementing various strategies including partnerships, mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in January 2022, in vivo base-editing programs for three objectives for rare genetic defects of the muscle, liver, and central nervous system will be the focus of an exclusive four-year collaborative research between Pfizer Inc. and Beam Therapeutics Inc. A four-year research partnership combines Beam's expertise in base editing and mRNA/LNP delivery technologies with Pfizer's extensive experience in global drug discovery, including initiatives involving messenger RNA (mRNA),gene therapy, and lipid nanoparticles (LNP). Some prominent players in the global mRNA therapeutics market include:

• Moderna, Inc.

• BioNTech SE

• CureVac N.V.

• Arcturus Therapeutics

• Translate Bio, Inc.

• GSK plc.

• Argos Therapeutics Inc.

• Sangamo Therapeutics, Inc.

• Pfizer Inc.

• AstraZeneca plc.

• CRISPR Therapeutics AG

mRNA Therapeutics MarketReport Scope

Report Attribute	Details
Market size value in 2022	USD 33.02 billion
Revenue forecast in 2030	USD 37.76 billion
Growth rate	CAGR of 1.7% from 2022 to 2030
Base year for estimation	2021
Historical data	2020
Forecast period	2022 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2022 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Application, type, end-use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Germany; U.K.; France, Italy, Spain, China; Japan; India, Australia, South Korea, Brazil; Mexico, South Africa; Saudi Arabia, UAE
Key companies profiled	Moderna, Inc.; BioNTech SE; CureVac N.V.; Arcturus Therapeutics; Translate Bio, Inc.; GSK plc.; Argos Therapeutics Inc.; Sangamo Therapeutics, Inc.; Pfizer Inc.; AstraZeneca plc.; CRISPR Therapeutics AG
Customization scope	Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.Explore purchase options

GlobalmRNA Therapeutics Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this report, Grand View Research has segmented the global mRNA therapeutics market report on the basis of application, type, end-use, and region:

• Application Outlook (Revenue, USD Million, 2020 - 2030)

  • Rare Genetic Diseases

  • Oncology

  • Respiratory Diseases

  • Infectious Diseases

  • Others

• Type Outlook (Revenue, USD Million, 2020 - 2030)

  • Prophylactic Vaccines

  • Therapeutic Vaccines

  • Therapeutic Drugs

• End-use Outlook (Revenue, USD Million, 2020 - 2030)

  • Hospitals & Clinics

  • Research Organizations

  • Others

• Regional Outlook (Revenue, USD Million, 2020 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE